Latest period
$3.34B
YoY change
+16.1%
5Y CAGR
+65.2%
Peak year (2023)
$4.48B
Latest annual
$4.24B
Cash on Hand history chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: $4.24B
Cash on Hand growth chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: +16.1%
Cash on Hand history table for Novo Nordisk (NVO) from 1985 to 2025
| 2025 | $4.24B | +16.1% | +$587.50M | ||
| 2024 | $3.65B | -18.4% | −$823.49M | ||
| 2023 | $4.48B | +31.9% | +$1.08B | ||
| 2022 | $3.39B | +26.9% | +$719.64M | ||
| 2021 | $2.67B | +676.9% | +$2.33B | ||
| 2020 | $344.29M | -1.3% | −$4.54M | ||
| 2019 | $348.83M | -85.5% | −$2.05B | ||
| 2018 | $2.40B | -21.0% | −$636.80M | ||
| 2017 | $3.04B | +3.7% | +$109.38M | ||
| 2016 | $2.93B | -1.7% | −$51.82M | ||
| 2015 | $2.98B | +15.3% | +$395.99M | ||
| 2014 | $2.58B | -3.3% | −$89.57M | ||
| 2013 | $2.67B | -6.1% | −$174.53M | ||
| 2012 | $2.85B | -6.7% | −$203.23M | ||
| 2011 | $3.05B | +5.9% | +$169.80M | ||
| 2010 | $2.88B | +16.7% | +$413.33M | ||
| 2009 | $2.47B | +29.1% | +$557.04M | ||
| 2008 | $1.91B | +32.2% | +$465.99M | ||
| 2007 | $1.45B | +60.1% | +$542.83M | ||
| 2006 | $903.06M | +13.3% | +$106.26M | ||
| 2005 | $796.81M | +9.5% | +$68.94M | ||
| 2004 | $727.86M | +38.9% | +$203.85M | ||
| 2003 | $524.02M | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — | ||
| 1989 | — | — | — | ||
| 1988 | — | — | — | ||
| 1987 | — | — | — | ||
| 1986 | — | — | — | ||
| 1985 | — | — | — |
- 2025$4.24B+16.1%
- 2024$3.65B-18.4%
- 2023$4.48B+31.9%
- 2022$3.39B+26.9%
- 2021$2.67B+676.9%
- 2020$344.29M-1.3%
- 2019$348.83M-85.5%
- 2018$2.40B-21.0%
- 2017$3.04B+3.7%
- 2016$2.93B-1.7%
- 2015$2.98B+15.3%
- 2014$2.58B-3.3%
- 2013$2.67B-6.1%
- 2012$2.85B-6.7%
- 2011$3.05B+5.9%
- 2010$2.88B+16.7%
- 2009$2.47B+29.1%
- 2008$1.91B+32.2%
- 2007$1.45B+60.1%
- 2006$903.06M+13.3%
- 2005$796.81M+9.5%
- 2004$727.86M+38.9%
- 2003$524.02M—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
- 1989——
- 1988——
- 1987——
- 1986——
- 1985——
Cash on Hand values are taken from Novo Nordisk's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Cash on Hand at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's latest reported cash and short-term investments is $3.34B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual cash and short-term investments for Novo Nordisk (NVO) came in at 26.96B DKK – edged up 2.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Novo Nordisk cash and short-term investments compounded at +66.7% per year, with mixed annual results across the window.
Novo Nordisk cash and short-term investments peaked at 30.23B DKK in 2023; the latest annual figure is 26.96B DKK in 2025 (10.8% below peak).
30.23B DKK stands as the all-time-high annual cash and short-term investments, posted in 2023, against a low of 798.68M DKK during 1998.
Novo Nordisk Cash on Hand by Year
Novo Nordisk Cash on Hand 2025: $4.24B
Novo Nordisk cash and short-term investments in 2025 was 26.96B DKK ($4.24B), edged up 2.5% from 2024.
Novo Nordisk Cash on Hand 2024: $3.65B
2024's cash and short-term investments for Novo Nordisk came in at 26.31B DKK ($3.65B), declined 13.0% below 2023.
Novo Nordisk Cash on Hand 2023: $4.48B
Novo Nordisk posted cash and short-term investments of 30.23B DKK ($4.48B) in 2023, grew 28.2% from 2022. This figure represents the highest annual value in the available history.
Novo Nordisk Cash on Hand 2022: $3.39B
In 2022, Novo Nordisk reported cash and short-term investments of 23.57B DKK ($3.39B), surged 34.8% from 2021.
Novo Nordisk Cash on Hand 2021: $2.67B
Novo Nordisk cash and short-term investments in 2021 was 17.48B DKK ($2.67B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Cash on Hand
Healthcare peers of Novo Nordisk (NVO), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $10.11B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation